Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Short-term Investments (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Short-term Investments data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 53.82% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 53.82%, while the annual FY2025 figure was $2.3 million, 53.82% up from the prior year.
  • Short-term Investments reached $2.3 million in Q4 2025 per CAI's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $2.3 million in Q4 2025 and bottomed at $1.5 million in Q4 2024.